BofA cuts C.H. Robinson stock price target on RXO acquisition

BofA Securities has increased its price target for Vaxcyte shares (NASDAQ: PCVX) to $146, up from $130, following positive data from its OPUS-1 Phase 3 trial. The stock is currently trading at $73.82, with a range of analyst targets stretching from $67 to $163, indicating substantial upside potential. The firm's upgrade comes after an investor call focused on the OPUS-1 trial results, regulatory implications, and the commercial strategy for VAX-31.

OPUS-1 met its primary endpoint, supporting a broad 31-serotype label for VAX-31, which is expected to secure an adult biologics license application. However, the firm noted that Regulators might compare VAX-31 with the Capvaxive arm, as two individual-comparator misses exceeded the historical 0.5 non-inferiority standard but met a more stringent 0.667 threshold compared to Prevnar20.

VAX-31's extensive serotype coverage leaves little room for competitors to optimize, positioning the product favorably in the adult market. Since the trial results, the stock has experienced a 30% surge over the past week. Four analysts have revised their earnings estimates upward for the upcoming period. However, InvestingPro's Fair Value analysis suggests the stock might be overvalued at its current level.